Agenus (AGEN) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

AGEN Stock Forecast


Agenus stock forecast is as follows: an average price target of $8.00 (represents a 179.72% upside from AGEN’s last price of $2.86) and a rating consensus of 'Hold', based on 4 wall street analysts offering a 1-year stock forecast.

AGEN Price Target


The average price target for Agenus (AGEN) is $8.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $9.00 to $7.00. This represents a potential 179.72% upside from AGEN's last price of $2.86.

AGEN Analyst Ratings


Hold

According to 4 Wall Street analysts, Agenus's rating consensus is 'Hold'. The analyst rating breakdown for AGEN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (25.00%), 3 'Hold' (75.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Agenus Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 19, 2024Biren AminJefferies$7.00$5.9916.86%144.76%
Jul 19, 2024Colleen KusyRobert W. Baird$8.00$7.309.59%179.72%
Jul 18, 2024Emily BodnarH.C. Wainwright$9.00$7.9812.85%214.69%
Jul 01, 2024Emily BodnarH.C. Wainwright$40.00$16.75138.81%1298.60%
Row per page
Go to

The latest Agenus stock forecast, released on Jul 19, 2024 by Biren Amin from Jefferies, set a price target of $7.00, which represents a 16.86% increase from the stock price at the time of the forecast ($5.99), and a 144.76% increase from AGEN last price ($2.86).

Agenus Price Target by Period


1M3M12M
# Anlaysts--4
Avg Price Target--$16.00
Last Closing Price$2.86$2.86$2.86
Upside/Downside-100.00%-100.00%459.44%

In the current month, the average price target of Agenus stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Agenus's last price of $2.86. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Aug 14, 2024B. RileyBuyBuyHold
Jul 19, 2024Jefferies-HoldDowngrade
Jul 18, 2024William Blair-Market PerformDowngrade
Jul 18, 2024H.C. WainwrightBuyNeutralDowngrade
Jul 01, 2024H.C. WainwrightBuyBuyHold
Row per page
Go to

Agenus's last stock rating was published by B. Riley on Aug 14, 2024. The company gave AGEN a "Buy" rating, the same as its previous rate.

Agenus Financial Forecast


Agenus Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$83.80M$24.31M$25.30M$22.90M$28.39M$22.77M$20.93M$25.94M$20.26M$252.95M$10.73M$11.72M$31.26M$14.83M$26.95M$15.13M$34.50M$19.94M
Avg Forecast$96.42M$92.53M$86.73M$80.91M$52.53M$64.61M$64.21M$26.31M$36.46M$33.48M$63.48M$47.17M$47.05M$24.33M$24.13M$22.98M$17.83M$20.69M$18.70M$11.80M$37.74M$183.10M$20.41M$14.53M$16.23M$14.00M$9.33M$12.35M$13.03M$15.60M
High Forecast$174.92M$167.85M$157.32M$146.76M$95.29M$117.21M$116.47M$47.72M$78.51M$60.73M$63.48M$47.17M$64.49M$24.33M$43.78M$41.68M$32.34M$20.69M$18.70M$11.80M$37.74M$183.10M$20.41M$14.53M$16.23M$14.00M$9.33M$12.35M$13.03M$15.60M
Low Forecast$62.00M$59.50M$55.76M$52.02M$33.77M$41.55M$41.28M$16.91M$18.75M$21.52M$63.48M$47.17M$22.42M$24.33M$15.52M$14.77M$11.46M$20.69M$18.70M$11.80M$37.74M$183.10M$20.41M$14.53M$16.23M$14.00M$9.33M$12.35M$13.03M$15.60M
# Analysts111111113111311111111111999988
Surprise %------------1.78%1.00%1.05%1.00%1.59%1.10%1.12%2.20%0.54%1.38%0.53%0.81%1.93%1.06%2.89%1.22%2.65%1.28%

Agenus's average Quarter revenue forecast for Mar 24 based on 1 analysts is $47.17M, with a low forecast of $47.17M, and a high forecast of $47.17M. AGEN's average Quarter revenue forecast represents a -43.71% decrease compared to the company's last Quarter revenue of $83.80M (Dec 23).

Agenus EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111113111311111111111999988
EBITDA------------$-4.36M$442.00K$2.14M$-52.15M$-52.82M$-39.41M$-34.22M$-34.28M$-47.28M$196.81M$-64.89M$-36.06M$-19.57M$-33.09M$-31.06M$-28.94M$-16.54M$-33.14M
Avg Forecast$-61.86M$-59.36M$-55.64M$-51.90M$-33.70M$-41.45M$-41.19M$-16.88M$-23.39M$-21.47M$-40.72M$-37.59M$-30.19M$-15.61M$-15.48M$-40.21M$-14.53M$-13.06M$-11.80M$-43.00M$-23.82M$-115.56M$-12.88M$-40.71M$-10.24M$-8.84M$-5.89M$-30.69M$-8.22M$-9.85M
High Forecast$-39.77M$-38.17M$-35.77M$-33.37M$-21.67M$-26.65M$-26.48M$-10.85M$-12.03M$-13.81M$-40.72M$-30.08M$-14.38M$-15.61M$-9.95M$-32.17M$-11.62M$-13.06M$-11.80M$-34.40M$-23.82M$-115.56M$-12.88M$-32.57M$-10.24M$-8.84M$-5.89M$-24.55M$-8.22M$-9.85M
Low Forecast$-112.21M$-107.68M$-100.92M$-94.15M$-61.13M$-75.19M$-74.72M$-30.61M$-50.37M$-38.96M$-40.72M$-45.11M$-41.37M$-15.61M$-28.08M$-48.25M$-17.43M$-13.06M$-11.80M$-51.60M$-23.82M$-115.56M$-12.88M$-48.85M$-10.24M$-8.84M$-5.89M$-36.83M$-8.22M$-9.85M
Surprise %------------0.14%-0.03%-0.14%1.30%3.64%3.02%2.90%0.80%1.99%-1.70%5.04%0.89%1.91%3.75%5.28%0.94%2.01%3.37%

3 analysts predict AGEN's average Quarter EBITDA for Dec 23 to be $-30.19M, with a high of $-14.38M and a low of $-41.37M. This is -6929.29% lower than Agenus's previous annual EBITDA (Sep 23) of $442.00K.

Agenus Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111113111311111111111999988
Net Income------------$-48.58M$-62.25M$-69.07M$-67.85M$-97.40M$-74.28M$-51.10M$-63.47M$-84.18M$178.55M$-83.29M$-53.68M$-37.61M$-51.15M$-47.48M$-44.67M$-30.05M$-45.47M
Avg Forecast$-41.36M$-43.45M$-47.36M$-51.63M$-57.97M$-46.33M$-39.11M$-54.20M$-56.10M$-49.86M$-22.99M$-57.74M$-23.00M$-84.07M$-84.05M$-61.75M$-15.03M$-77.51M$-95.07M$-66.04M$-65.10M$188.77M$-100.59M$-60.60M$-90.94M$-107.47M$-112.99M$-47.38M$-157.08M$-157.08M
High Forecast$-22.16M$-23.28M$-25.38M$-27.67M$-31.06M$-24.83M$-20.96M$-29.04M$16.43M$-26.72M$-12.32M$-46.19M$7.67M$-45.05M$-45.04M$-49.40M$-12.02M$-77.51M$-95.07M$-52.84M$-65.10M$188.77M$-100.59M$-48.48M$-90.94M$-107.47M$-112.99M$-37.91M$-157.08M$-157.08M
Low Forecast$-85.12M$-89.44M$-97.48M$-106.26M$-119.31M$-95.36M$-80.50M$-111.55M$-81.89M$-102.62M$-47.31M$-69.28M$-57.51M$-173.04M$-172.98M$-74.10M$-18.04M$-77.51M$-95.07M$-79.25M$-65.10M$188.77M$-100.59M$-72.72M$-90.94M$-107.47M$-112.99M$-56.86M$-157.08M$-157.08M
Surprise %------------2.11%0.74%0.82%1.10%6.48%0.96%0.54%0.96%1.29%0.95%0.83%0.89%0.41%0.48%0.42%0.94%0.19%0.29%

Agenus's average Quarter net income forecast for Dec 21 is $-65.10M, with a range of $-65.10M to $-65.10M. AGEN's average Quarter net income forecast represents a -136.46% decrease compared to the company's last Quarter net income of $178.55M (Sep 21).

Agenus SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111113111311111111111999988
SG&A------------$21.18M$18.91M$20.41M$18.24M$25.04M$18.11M$18.91M$18.95M$21.97M$21.39M$16.65M$16.35M$20.03M$14.38M$14.20M$10.61M$12.32M$11.51M
Avg Forecast$49.50M$47.50M$44.52M$41.53M$26.97M$33.17M$32.96M$13.51M$18.72M$17.19M$32.59M$22.64M$24.16M$12.49M$12.39M$11.79M$2.92M$10.26M$9.27M$5.85M$18.72M$90.82M$10.12M$7.21M$8.05M$6.94M$4.63M$11.26M$6.46M$7.74M
High Forecast$89.80M$86.17M$80.77M$75.34M$48.92M$60.17M$59.79M$24.50M$40.31M$31.18M$32.59M$27.17M$33.11M$12.49M$22.47M$21.40M$3.50M$10.26M$9.27M$5.85M$18.72M$90.82M$10.12M$7.21M$8.05M$6.94M$4.63M$13.51M$6.46M$7.74M
Low Forecast$31.83M$30.54M$28.63M$26.71M$17.34M$21.33M$21.19M$8.68M$9.63M$11.05M$32.59M$18.12M$11.51M$12.49M$7.97M$7.58M$2.33M$10.26M$9.27M$5.85M$18.72M$90.82M$10.12M$7.21M$8.05M$6.94M$4.63M$9.00M$6.46M$7.74M
Surprise %------------0.88%1.51%1.65%1.55%8.59%1.76%2.04%3.24%1.17%0.24%1.64%2.27%2.49%2.07%3.07%0.94%1.91%1.49%

Agenus's average Quarter SG&A projection for Mar 24 is $22.64M, based on 1 Wall Street analysts, with a range of $18.12M to $27.17M. The forecast indicates a 6.93% rise compared to AGEN last annual SG&A of $21.18M (Dec 23).

Agenus EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111113111311111111111999988
EPS------------$-0.13$-0.16$-0.20$-0.21$-0.35$-0.26$-0.18$-0.25$-0.36$0.76$-0.37$-0.27$-0.19$-0.28$-0.28$-0.31$-0.21$-0.33
Avg Forecast$-1.92$-2.02$-2.20$-2.40$-2.69$-2.15$-1.81$-2.52$-2.60$-2.31$-1.07$-3.21$-1.07$-3.90$-3.90$-4.14$-4.35$-3.68$-4.51$-5.84$-3.09$8.96$-4.78$-6.02$-4.32$-5.10$-5.36$-6.54$-7.46$-7.46
High Forecast$-1.03$-1.08$-1.18$-1.28$-1.44$-1.15$-0.97$-1.35$0.76$-1.24$-0.57$-1.72$0.36$-2.09$-2.09$-2.22$-2.33$-3.68$-4.51$-5.84$-3.09$8.96$-4.78$-6.02$-4.32$-5.10$-5.36$-6.54$-7.46$-7.46
Low Forecast$-3.95$-4.15$-4.52$-4.93$-5.54$-4.43$-3.74$-5.18$-3.80$-4.76$-2.20$-6.60$-2.67$-8.03$-8.03$-8.53$-8.95$-3.68$-4.51$-5.84$-3.09$8.96$-4.78$-6.02$-4.32$-5.10$-5.36$-6.54$-7.46$-7.46
Surprise %------------0.12%0.04%0.05%0.05%0.08%0.07%0.04%0.04%0.12%0.08%0.08%0.04%0.04%0.05%0.05%0.05%0.03%0.04%

According to 1 Wall Street analysts, Agenus's projected average Quarter EPS for Dec 21 is $-3.09, with a low estimate of $-3.09 and a high estimate of $-3.09. This represents a -506.72% decrease compared to AGEN previous annual EPS of $0.76 (Sep 21).

Agenus Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
XFORX4 Pharmaceuticals$0.37$3.67891.89%Buy
ADCTADC Therapeutics SA$1.94$9.33380.93%Buy
ADAPAdaptimmune Therapeutics$0.64$2.83342.19%Buy
PDSBPDS Bio$2.20$9.00309.09%Buy
AFMDAffimed$2.64$7.50184.09%Buy
AGENAgenus$2.86$8.00179.72%Hold
LPTXLeap Therapeutics$2.58$5.50113.18%Buy
VKTXViking Therapeutics$51.63$102.4098.33%Buy
MREOMereo BioPharma Group$3.68$6.7583.42%Buy
EWTXEdgewise Therapeutics$31.98$45.0040.71%Buy
MDGLMadrigal Pharmaceuticals$329.24$315.75-4.10%Buy
TGTXTG Therapeutics$34.55$27.60-20.12%Buy

AGEN Forecast FAQ


Is Agenus a good buy?

No, according to 4 Wall Street analysts, Agenus (AGEN) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 25.00% of AGEN's total ratings.

What is AGEN's price target?

Agenus (AGEN) average price target is $8 with a range of $7 to $9, implying a 179.72% from its last price of $2.86. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Agenus stock go up soon?

According to Wall Street analysts' prediction for AGEN stock, the company can go up by 179.72% (from the last price of $2.86 to the average price target of $8), up by 214.69% based on the highest stock price target, and up by 144.76% based on the lowest stock price target.

Can Agenus stock reach $4?

AGEN's average twelve months analyst stock price target of $8 supports the claim that Agenus can reach $4 in the near future.

What are Agenus's analysts' financial forecasts?

Agenus's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $207.66M (high $376.7M, low $133.52M), average EBITDA is $-133M (high $-85.652M, low $-242M), average net income is $-198M (high $-106M, low $-407M), average SG&A $106.61M (high $193.39M, low $68.54M), and average EPS is $-9.17 (high $-4.914, low $-18.874). AGEN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $356.59M (high $646.86M, low $229.28M), average EBITDA is $-229M (high $-147M, low $-415M), average net income is $-184M (high $-98.491M, low $-378M), average SG&A $183.06M (high $332.08M, low $117.7M), and average EPS is $-8.529 (high $-4.57, low $-17.555).

Did the AGEN's actual financial results beat the analysts' financial forecasts?

Based on Agenus's last annual report (Dec 2023), the company's revenue was $785.91M, beating the average analysts forecast of $118.49M by 563.25%. Apple's EBITDA was $0, missing the average prediction of $-101M by -100.00%. The company's net income was $0, missing the average estimation of $-253M by -100.00%. Apple's SG&A was $0, missing the average forecast of $60.83M by -100.00%. Lastly, the company's EPS was $0, missing the average prediction of $-13.011 by -100.00%. In terms of the last quarterly report (Dec 2023), Agenus's revenue was $83.8M, beating the average analysts' forecast of $47.05M by 78.09%. The company's EBITDA was $-4.359M, missing the average prediction of $-30.185M by -85.56%. Agenus's net income was $-48.582M, beating the average estimation of $-23.005M by 111.18%. The company's SG&A was $21.18M, missing the average forecast of $24.16M by -12.33%. Lastly, the company's EPS was $-0.13, missing the average prediction of $-1.067 by -87.82%